SCI/D Treatment Update

Four SCI/D treatments in different stages of trials offer hope.

If you’ve lived with a spinal cord injury (SCI) for years, you’ve probably heard that a breakthrough is on the way more than once. So, what treatment developments are forming for people with SCI right now, and how close are they? With the requisite grain of salt that accompanies proposed cures and technological advances, here are four treatments in development, ordered from most advanced to earliest stage, and how much further they need to go before being potentially proven practical for making life easier for people with SCI/D.

A daily injection for hand function (Phase 3)

NervGen’s NVG-291 is the treatment that’s most advanced from concept to reality. It’s a daily injected drug aimed at a pathway that blocks nerve repair. The company calls it neuroreparative, meaning it aims to promote repair of the nervous system rather than manage symptoms. The Phase 3 RESTORE trial will enroll about 150 adults in the U.S. and Canada who have chronic, traumatic, cervical, motor-incomplete injuries; all four criteria are necessary. Participants get a daily injection for 12 weeks, and the main measure of effectiveness is hand function. The first participant took the starting dose in October. NervGen expects to finish enrollment in the second half of 2027 and report topline results in the first half of 2028.

The Food and Drug Administration has granted Breakthrough Therapy designation based on preliminary evidence from an earlier, smaller study. That designation can speed review, but it isn’t the same as an approval. NervGen’s latest release gives no figures from that study, and the company says it is finalizing a journal manuscript. The trial is limited to a specific type of injury, and the drug’s benefit in people is not yet proven.

An implanted stimulator for bladder and bowel function (early human trial)

At London’s Royal National Orthopaedic Hospital, the ImPRESS trial is testing whether an implanted epidural stimulator can improve bladder and bowel function after an SCI. Eight people have received the device so far, and five have finished the trial. Interim results show the stimulator suppressed the urge to urinate and increased bladder capacity by an average of 100%. While these are certainly promising results, lead researcher Lynsey Duffell, PhD, cautions that it is too early to report outcome results.

The size of the study seems to be the main cause for reservation at this point. Plans call for up to 20 people with chronic injuries and a bladder that has been confirmed as overactive; people with a transected cord or earlier surgery on the bladder sphincters are excluded from the study. The trial has two phases: Surgeons implant the stimulator and test whether a person responds, then participants use it at home for 12 weeks alongside pelvic floor muscle training. The interim findings reported so far concern the bladder as opposed to the bowels, and the team said last year that it expected results in 2027.

An implant grown from the patient’s own cells (preclinical)

Matricelf, an Israeli company working with Tel Aviv University, is developing an implant called NewRal, made from a patient’s own blood and abdominal tissue. Each one is custom-built and takes several months to produce. No one has received it yet. The surgery would remove scar tissue at the injury site and replace it with a small engineered cord made from those cells, which is meant to avoid rejection.

On Nov. 5, the company reported results from a comprehensive preclinical study in rats with chronic SCI. About 63% of treated animals improved by at least five points on a standard motor scale, compared with 11.5% of control subjects. At 12 weeks, average scores were 9.0 in treated animals and 5.4 in controls. Matricelf says the motor-score differences were statistically significant, but notes that significance for the responder comparison hasn’t been established and that the findings do not establish efficacy in humans.

Tel Aviv University said in August that preparations have begun to identify patients for a possible first treatment in 2027. Matricelf estimates treatment of the first patient could begin in the front half of 2027 if everything goes as planned, and Israel’s health ministry has given preliminary approval for compassionate-use trials in eight patients. Last year’s reporting suggested a young person injured within the past year to 18 months and paralyzed from the waist down would get the first implant, but no patient has been announced.

An ultrasound patch for the hospital stay after injury (animal studies)

Johns Hopkins’ MUSIC is the earliest-stage project, and it targets a different moment in the life of a person with SCI/D: the hospital stay after injury. It is a Band-Aid-sized ultrasound device placed over the spinal cord at the injury site during surgery and removed later. It would give real-time views of blood flow, and a more exploratory mode might one day respond when flow in small vessels becomes abnormal. The goal is to reduce risks such as stroke, blindness or further loss of movement during immediate recovery after surgery.

A study published in the Nov. 4 Science Advances showed the device could be implanted temporarily and provide real-time feedback on blood flow and imaging, but it was done in animals, not people. The team plans more animal studies, funded mainly by a $13.48 million Department of Defense award. The release also notes that two of the researchers hold related patents and have ties to companies including Globus Medical. As designed, MUSIC wouldn’t help or affect people already living with chronic SCI, but it could eventually change acute care.

Leave a Reply

Search

Recent Posts From PN Online

error: Content is protected !!